We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Managing treatment-related adverse events associated with EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer.
- Authors
Hirsh, V.
- Abstract
Non-small-cell lung cancer (NSCLC) has the highest prevalence of all types of lung cancer, which is the second most common cancer and the leading cause of cancer-related mortality in Canada. The need for more effective and less toxic treatment options for NSCLC has led to the development of agents targeting the epidermal growth factor receptor (EGFR)-mediated signalling pathway, such as EGFR tyrosine kinase inhibitors (EGFR-TKIS). Although EGFR-TKIS are less toxic than traditional anti-neoplastic agents, they are commonly associated with acneiform-like rash and diarrhea. This review summarizes the clinical presentation and causes of EGFR-TKI-induced rash and diarrhea, and presents strategies for effective assessment, monitoring, and treatment of these adverse effects. Strategies to improve the management of EGFR-TKI-related adverse events should improve clinical outcomes, compliance, and quality of life in patients with advanced NSCLC.
- Subjects
CANADA; LUNG cancer treatment; CANCER treatment; CANCER patients; PROTEIN-tyrosine kinases; AMINO acids; PROTEIN kinases
- Publication
Current Oncology, 2011, Vol 18, Issue 3, p126
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3747/co.v18i3.877